Study finds NHS vaccine 'cuts risk of dementia'

The Shingrix vaccine has been linked to a 17% drop in dementia diagnoses in the six years after vaccination than the previously-used Zostavax jab, according to a new study Our community members are treated to special offers, promotions and adverts from us and our partners. You can check out at any time. More info The shingles vaccine provided by the NHS significantly reduces the risk of dementia, a recent study has revealed.

The research, which experts have deemed "convincing", indicates that the Shingrix vaccine is associated with at least a 17% decrease in dementia diagnoses in the six years following vaccination compared to the previously used Zostavax jab. Researchers from the University of Oxford suggest this translates to an additional five to nine months of life without dementia for those administered the Shingrix jab as opposed to other vaccines. Both genders benefited from the newer jab, but the effects were more pronounced in women, according to the study.

Shingles, a common condition characterised by a painful rash, can occasionally result in severe complications such as deafness, persistent pain, and blindness. The likelihood of contracting shingles increases with age, and it tends to cause more serious issues in older demographics, reports Gloucestershire Live . Dr Maxime Taquet, an academic clinical lecturer in the department of psychiatry at Oxford, who spearheaded the study involving over 200,000 individuals, said: "The size and nature of this study makes thes.